Spravato Breakthrough Treatment
Spravato (esketamine therapy) is a promising treatment for those with treatment-resistant depression, offering rapid relief where traditional antidepressants may fail.
- Spravato’s Unique Effectiveness. Spravato opens new doors for those who have exhausted other treatment options, providing fast-acting relief unlike traditional antidepressants.
- Challenges with Traditional Antidepressants. Over 65% of people prescribed traditional antidepressants do not respond to them, leading to treatment-resistant depression (TRD).
- Neuroplasticity and New Treatments Enhancing neuroplasticity, the brain’s ability to reshape itself, is a new approach to treating depression, focusing on proteins like Brain-Derived Neurotrophic Factor (BDNF).
- How Spravato Works. Spravato, an FDA-approved nasal spray, targets NMDA receptors to reset and provide rapid relief, often within hours.
- 22.5% of patients achieved remission in clinical trials at week 4, compared to only 7.6% in the placebo group.
- Instead of working on serotonin, it targets NMDA receptors in the brain, helping rewire how you process emotions.
- It’s done in a medical setting—you won’t be left on your own. Each session is supervised to ensure your safety and comfort.
- After an initial induction period of 2 months, patients come into the clinic for a session every few weeks to maintain remission of symptoms, rather than taking a daily pill.
- Traditional side effects from antidepressants like weight gain and sexual dysfunction don’t occur as the half-life of Spravato is only 2 hours.
- Patient Suitability for Spravato. Spravato is designed for adults with treatment-resistant depression or major depressive disorder with suicidal thoughts, and it is covered by most insurance plans, including Medicaid.
- Availability and Support. Spravato is available at certified treatment centers like Rose NeuroSpa, and patients are supported throughout their treatment sessions.